Aquestive Therapeutics (AQST) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Shattuck Labs (STTK) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 130.8% versus a loss of 22.6%. Over five years, AQST leads with a +19.4% price change compared with -70.7% for STTK. Aquestive Therapeutics is the larger company by market cap ($586.1 million vs $554.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | STTK |
|---|---|---|
| Share price | $4.67 | $5.52 |
| Market cap | $586.14M | $554.01M |
| 1-day change | +1.08% | -2.39% |
| YTD return | -28.48% | +54.93% |
| 1-year return | -22.61% | +130.82% |
| 5-year return | +19.38% | -70.74% |
| EPS (TTM) | $-0.66 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $8.33 |
| 52-week low | $2.93 | $1.70 |
| Distance from 52-week high | -38.15% | -33.73% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +99.79% | +175.72% |
| Average volume | 2.66M | 1.20M |
| Shares outstanding | 125.51M | 100.36M |
| Employees | 147 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed AQST by 153.4 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
AQST vs STTK FAQ
Which is bigger, Aquestive Therapeutics or Shattuck Labs?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $586.14M compared with $554.01M for Shattuck Labs (STTK).
Which stock has performed better over the past year, AQST or STTK?
STTK returned +130.82% over the past 12 months, compared with -22.61% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.